Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 21, 2013; 19(27): 4356-4362
Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4356
Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4356
Table 1 ATP7B mutations in patients with Wilson’s disease treated with zinc sulphate
Mutation analysis | n |
p.H1069Q/p.H1069Q | 22 |
Diagnosis not confirmed by mutation analysis | 1 |
p.H1069Q/- | 7 |
p.H1069Q/p.Q1351X | 2 |
p.H1069Q/p.A1135fs | 2 |
p.V845fs/- | 2 |
p.H1069Q/p.E507fs | 1 |
p.H1069Q/p.C985Y | 1 |
p.H1069Q/p.L1325fs | 1 |
p.H1969Q/p.W779X | 1 |
p.H1069Q/p.R969Q | 1 |
p.H1069Q/p.T737I | 1 |
p.H1069Q/p.P1273L | 1 |
p.H1069Q/p.V772_I774del | 1 |
p.H1069Q/p.Arg969Gln | 1 |
p.H1069Q/p.G1341R | 1 |
p.A1135fs/p.A1135fs | 1 |
p.A1135fs/p.R1319X | 1 |
p.G1158fs/p.G1158fs | 1 |
p.W779X/p.W779R | 1 |
p.Q1351X/- | 1 |
p.A1135fs/- | 1 |
p.N1270S/- | 1 |
Table 2 Characteristic of patients with side effects during zinc therapy
No. | Sex | Age of onset of symptoms (yr) | Age of diagnosis (yr) | Mutation analysis | Zinc sulphate therapy-dosagescheme (mg) | Treatment history | Cause of conversion to D-penicillamine | Cause of conversion to zinc acetate | Cause of additional intervention | Endoscopic examination | |
1 | M | 7 | 8 | p.V845fs | - | 2 × 45 | ZS - P - ZA | Abdominal pain | Rash | No | |
2 | F | Asymptomatic, positive family history | 15 | p.V845fs | - | 3 × 45 | ZS - P - ZA | Abdominal pain | Abdominal pain | No | |
3 | M | Asymptomatic, positive family history | 6 | p.Q1351X | - | 3 × 45 | ZS - P | Abdominal pain | No | ||
4 | M | 7 | 16 | p.W779X | p.W779R | 3 × 45 | ZS - P | Abdominal pain, loss of appetite | No | ||
5 | F | 7 | 9 | p.H1069Q | p.H1069Q | 3 × 45 | ZS - P | Vomiting | No | ||
6 | M | Lack of data | 12 | p.H1069Q | p.P1273L | 3 × 45 | ZS + PPI | Abdominal pain, symptoms of GERD | No | ||
7 | M | 11 | 12 | - | - | 3 × 45 | ZS - ADS | Abdominal pain | No | ||
8 | F | 11 | 11 | p.N1270S | - | 3 × 45 | ZS - P | Nausea | No | ||
9 | M | 12 | 13.5 | p.G1158fs | p.G1158fs | 5 × 45 | ZS - P | Nausea, vomiting | No | ||
10 | F | 13 | 14 | p.H1069Q | p.Q1351X | 3 × 45 | ZS - ZA | Nausea | No | ||
11 | F | Lack of data | 12 | p.H1069Q | p.T737I | 3 × 45 | ZS - P | Nausea | No | ||
12 | M | 8 | 13 | p.H1069Q | p.V772_I774del | 3 × 45 | P - ZS - ADS | Nausea | No | ||
13 | F | 7 | 7 | p.H1069Q | p.G1341R | 2 × 45 | ZS - P | Abdominal pain | No | ||
14 | M | 7 | 7 | p.A1135fs | - | 2 × 45 | ZS - ZA - P | Elevated transaminases | Abdominal pain | No | |
15 | F | Asymptomatic, positive family history | 5 | p.H1069Q | p.H1069Q | 2 × 45 | ZS + PPI - P | Abdominal pain | Yes | ||
16 | F | 8 | 8 | p.H1069Q | p.H1069Q | 2 × 45 | ZS +PPI - P | Abdominal pain | Yes | ||
17 | F | 14 | 14 | - | - | 3 × 45 | ZS + PPI | Abdominal pain | Yes | ||
18 | F | 12 | 12 | - | - | 3 × 45 | ZS +PPI - P | Abdominal pain | Yes | ||
19 | M | Asymptomatic, positive family history | Lack of data | - | - | 2 × 45 | ZS +PPI - P | Abdominal pain | Yes | ||
20 | F | 10 | 10 | p.H1069Q | - | 3 × 45 | ZS + PPI | Abdominal pain | Yes | ||
21 | F | 9 | 9 | - | - | 1 × 45 | ZS + PPI | Abdominal pain | Yes |
Table 3 Characteristic of patients with persistent abdominal pain
No. | Abdominal pain before zinc sulphate therapy | Duration of zinc sulphate therapy before abdominal pain occurred (wk) | EGD before intervention | Intervention | Abdominal pain after intervention | EDG after intervention | Additional intervention | Abdominal pain after additional intervention | EGD after additional intervention |
1 | Yes | Lack of data | Gastritis with mucosal ulceration | PPI | Yes | Ulcer scar | No | - | - |
2 | No | 96 | Gastritis with mucosal ulceration | PPI | No | No | No | - | - |
3 | No | 28 | Gastritis with mucosal ulceration | PPI | Yes | Gastritis with mucosal ulceration | Conversion to D-penicillamine | No | No |
4 | No | 144 | Gastritis with mucosal ulceration | PPI | Yes | Gastritis | Conversion to D-penicillamine | No | No |
5 | No | 12 | Gastritis with mucosal erosion | PPI | No | No | No | - | - |
6 | No | 96 | Gastritis with mucosal ulceration | PPI | Yes | No | Conversion to D-penicillamine | No | Normal findings |
7 | No | 96 | Gastritis with mucosal erosion | PPI | Yes | No | Conversion to D-penicillamine | No | Normal findings |
Table 4 Characteristic of mutation analysis in two groups of patients with Wilson’s disease: with and without side effects during zinc sulphate therapy
Mutation analysis | No. of patients during zinc sulphate therapy | |
Without side effects | With side effects | |
Homozygous for p.H1069Q mutation | 16 | 3 |
Compound heterozygous for p.H1069Q mutation | 8 | 5 |
Carrier for p.H1069Q mutation | 4 | 1 |
Carrier for a mutation other than p.H1069Q | 0 | 5 |
Mutation other than p.H1069Q on two alleles | 2 | 2 |
Lack of data | 2 | 5 |
- Citation: Wiernicka A, Jańczyk W, Dądalski M, Avsar Y, Schmidt H, Socha P. Gastrointestinal side effects in children with Wilson's disease treated with zinc sulphate. World J Gastroenterol 2013; 19(27): 4356-4362
- URL: https://www.wjgnet.com/1007-9327/full/v19/i27/4356.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i27.4356